Contact
searchSearch
HMP Global
Login

HER2+ Breast Cancer

News
Promising Intracranial Activity With Trastuzumab Deruxtecan Among Patients With HER2-Positive/Low Metastatic Breast Cancer With Active Brain Metastases
08/07/2025
Allison Casey
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data,...
08/07/2025
Oncology
Seth Wander, MD, PhD; Rachel Abelman, MD, Massachusetts General Brigham Cancer Center
Videos
Omitting Carboplatin from Neoadjuvant Regimen for Patients With HER2-Positive Early Breast Cancer
07/31/2025
Seth Wander, MD
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth Wander, MD, PhD, Massachusetts General Brigham Cancer Center, discuss the phase 3 neoCARHP study.
Rachel Abelman, MD, and Seth...
07/31/2025
Oncology
News
Real-World Treatment Patterns, Outcomes of Patients With HER2-Low Metastatic Breast Cancer
06/24/2025
Allison Casey
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that...
06/24/2025
Oncology
Conference Coverage
Artificial Intelligence Assistance May Improve Accuracy of Identifying HER2-Low and HER2-Ultralow Breast Cancers
06/12/2025
Allison Casey
According to results from a multinational study, use of an artificial intelligence tool during the assessment of HER2 status improved accuracy of identifying HER2-low or HER2-ultralow breast cancer.
According to results from a multinational study, use of an artificial intelligence tool during the assessment of HER2 status improved accuracy of identifying HER2-low or HER2-ultralow breast cancer.
According to results from a...
06/12/2025
Oncology
FDA Approval
FDA Approves Trastuzumab Deruxtecan for HR-Positive, HER2-Low/-Ultralow Breast Cancer
01/28/2025
Stephanie Holland
Based on results from the phase 3 DESTINY-Breast 06 trial, the FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who experienced disease progression on or...
Based on results from the phase 3 DESTINY-Breast 06 trial, the FDA has approved trastuzumab deruxtecan for patients with HR-positive, HER2-low or HER2-ultralow unresectable or metastatic breast cancer who experienced disease progression on or...
Based on results from the phase...
01/28/2025
Oncology
Conference Coverage
Addition of Palbociclib to Anti-HER2 and Endocrine Therapy As New Standard of Care for Patients With HR-Positive, HER2-Positive Advanced Breast Cancer
12/16/2024
Allison Casey
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to final results from the AFT-38 PATINA trial, the addition of palbociclib to anti-HER2 therapy and endocrine therapy demonstrated a statistically significant and clinically meaningful improvement to progression-free survival among...
According to final results from...
12/16/2024
Oncology
Conference Coverage
Margetuximab Plus Paclitaxel and Pertuzumab for Patients With HER2-Positive Breast Cancer
12/13/2024
Allison Casey
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
According to results from the phase 2 MARGOT trial, margetuximab plus paclitaxel and pertuzumab did not improve the pathological complete response rate compared with trastuzumab plus paclitaxel and pertuzumab among patients with HER2-positive...
According to results from the...
12/13/2024
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/20/2024
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the...
06/20/2024
Oncology
Ruta Rao, MD; Seth Wander, MD, PhD; William Gradishar, MD
Roundtables
Managing Patients With HER2-Positive Metastatic Breast Cancer
06/17/2024
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
In this video, a panel of experts discuss the management of patients with HER2-positive metastatic breast cancer, including updated results from the DESTINY-Breast03 trial.
In this video, a panel of...
06/17/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Remains Superior to Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/07/2024
Allison Casey
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival results from the DESTINY-Breast03 trial, trastuzumab deruxtecan continues to show superiority over trastuzumab emtansine among patients with HER2-positive metastatic breast cancer.
According to updated survival...
06/07/2024
Oncology
Conference Coverage
Trastuzumab Deruxtecan Improves Progression-Free Survival Among Patients With HER2-Low Metastatic Breast Cancer
06/06/2024
Allison Casey
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from the phase 3 DESTINY-Breast06 trial, trastuzumab deruxtecan improved survival results among patients with HER2-low and -ultralow, HR-positive metastatic breast cancer.
According to first results from...
06/06/2024
Oncology

News

News
Promising Intracranial Activity With Trastuzumab Deruxtecan Among Patients With HER2-Positive/Low Metastatic Breast Cancer With Active Brain Metastases
08/07/2025
Allison Casey
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data,...
08/07/2025
Oncology
News
Real-World Treatment Patterns, Outcomes of Patients With HER2-Low Metastatic Breast Cancer
06/24/2025
Allison Casey
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that...
06/24/2025
Oncology
News
No Benefit from Addition of Atezolizumab to Standard of Care Among Patients With HER2-Positive Breast Cancer
12/08/2023
Allison Casey
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a...
12/08/2023
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction
07/10/2023
Gina Tomaine
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference...
07/10/2023
Oncology
News
Cardiac Safety of SB3 Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
05/09/2023
Allison Casey
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3...
05/09/2023
Oncology
News
Chemotherapy-Free, De-escalated Neoadjuvent Therapy for HR-Positive/HER2-Positive Early Breast Cancer
04/06/2023
Amber Denham
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2...
04/06/2023
Oncology
News
No Prognostic, Predictive Value of Young Age for Patients With HER2-Positive Early Breast Cancer
08/12/2022
Derek Cowsert
A study found young age to have no prognostic or predictive value for patients with HER2-positive early breast cancer.
A study found young age to have no prognostic or predictive value for patients with HER2-positive early breast cancer.
A study found young age to have...
08/12/2022
Oncology
News
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With HER2–Positive Breast Cancer
05/05/2022
Allison Casey
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to...
05/05/2022
Oncology
News
Trastuzumab Deruxtecan Outperforms Standard of Care in Previously Treated HER2–Positive, Metastatic Breast Cancer
04/14/2022
John Otrompke, BA, JD
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab...
04/14/2022
Oncology
News
Early-Phase Data Support Further Evaluation of Daraxonrasib in RAS-Mutant Non-Small Cell Lung Cancer
09/03/2026
Stephanie Holland
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that...
09/03/2026
Oncology
News
Etentamig Significantly Reduces Risk of Progression or Death in Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
09/03/2026
Stephanie Holland
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3...
09/03/2026
Oncology
News
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi...
09/02/2026
Oncology
News
Longer Follow-Up Reinforces Clinical Benefit of Perioperative Durvalumab in Resectable Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3...
09/02/2026
Oncology
News
Perioperative Pembrolizumab Nearly Doubles 5-Year Event-Free Survival in Patients With Resectable Non-Small Cell Lung Cancer
09/01/2026
Stephanie Holland
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase...
09/01/2026
Oncology
News
NEO100-01 Meets Primary End Point, Supporting Further Development in IDH1-Mutant Glioma
08/31/2026
Emily Estrada
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase...
08/31/2026
Oncology
News
Zanidatamab Plus Chemotherapy Improves Overall Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/31/2026
Stephanie Holland
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01...
08/31/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology
FDA Approval
FDA Approves First-in-Class Rusfertide to Reduce Phlebotomy Burden in Adult Patients With Polycythemia Vera
08/31/2026
Emily Estrada
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide...
08/31/2026
Oncology
FDA Approval
FDA Approves Ropeginterferon Alfa-2b for Adult Patients With Essential Thrombocythemia
08/31/2026
Emily Estrada
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the...
08/31/2026
Oncology

Interactive Features

Quiz
Quiz: Does Trastuzumab Deruxtecan Show Greater Efficacy than Standard of Care in HER2-Positive BC?
04/26/2022
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab deruxtecan was associated with significantly lower risk of disease progression over current standard of care for HER2-positive metastatic breast cancer.
True or false: Trastuzumab...
04/26/2022
Oncology
Test Your Knowledge
Quiz: Which Treatment Combination Improved OS in Patients with HER2+ Breast Cancer?
12/16/2021
Which treatment combination improved overall survival in patients with previously treated HER2+ breast cancer?
Which treatment combination improved overall survival in patients with previously treated HER2+ breast cancer?
Which treatment combination...
12/16/2021
Oncology
Test Your Knowledge
Quiz: Does PLD Plus Docetaxel and Trastuzumab Improve pCR in HER2+ Breast Cancer?
12/09/2021
True or false: Neoadjuvant PLD plus docetaxel and trastuzumab improved pathological complete response rates in patients with invasive HER2+ breast cancer.
True or false: Neoadjuvant PLD plus docetaxel and trastuzumab improved pathological complete response rates in patients with invasive HER2+ breast cancer.
True or false: Neoadjuvant PLD...
12/09/2021
Oncology
Test Your Knowledge
Quiz: Does Adding Trastuzumab to Chemotherapy Reduce Recurrence in Early-Stage HER2+ Breast Cancer?
11/22/2021
True or false: Trastuzumab plus chemotherapy demonstrated lower recurrence and mortality than chemotherapy alone in patients with early-stage HER2+ breast cancer.
True or false: Trastuzumab plus chemotherapy demonstrated lower recurrence and mortality than chemotherapy alone in patients with early-stage HER2+ breast cancer.
True or false: Trastuzumab plus...
11/22/2021
Oncology
Test Your Knowledge
Quiz: Does Dalpiciclib Plus Pryrotinib Yield Promise as Chemo-Free Alternative for HER2+BC?
11/17/2021
True or false: Interim results from a phase 2 trial found that dalpiciclib plus pyrotinib showed promise as a chemo-free regimen for patients with HER2+ breast cancer.
True or false: Interim results from a phase 2 trial found that dalpiciclib plus pyrotinib showed promise as a chemo-free regimen for patients with HER2+ breast cancer.
True or false: Interim results...
11/17/2021
Oncology
Quiz
Quiz: Does Adjuvant Olaparib or Placebo Provide Longer OS in HER2-Negative Breast Cancer?
08/20/2021
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
True or false: In a recent phase 3 study for patients with HER2-negative early breast cancer with BRCA1 or BRCA2 germline mutations, placebo induction showed superior survival benefit in comparison to adjuvant olaparib.
True or false: In a recent phase...
08/20/2021
Oncology
Test Your Knowledge
Quiz: When Can Trastuzumab Deruxtecan Be Administered in mHER2+ Breast Cancer?
04/19/2021
Can trastuzumab deruxtecan be administered in sequence, in both third and fourth line setting, among patients with metastatic HER2+ breast cancer?
Can trastuzumab deruxtecan be administered in sequence, in both third and fourth line setting, among patients with metastatic HER2+ breast cancer?
Can trastuzumab deruxtecan be...
04/19/2021
Oncology
Test Your Knowledge
Quiz: How is Cardiac Function Monitored During Anthracycline‑Based Therapy in HER2+BC?
04/09/2021
Due to possible cardiac toxicity during Herceptin and pertuzumab treatment in HER2+BC, patient cardiac function is monitored via:
Due to possible cardiac toxicity during Herceptin and pertuzumab treatment in HER2+BC, patient cardiac function is monitored via:
Due to possible cardiac toxicity...
04/09/2021
Oncology
Test Your Knowledge
Quiz: Better Outcomes for PIK3CA-Mutated HR+/HER2-Negative Metastatic Breast Cancer or TNBC?
08/15/2020
True or False: Patients with PIK3CA-mutated TNBC have better outcomes than those with PIK3CA-mutated HR+/HER2-negative metastatic breast cancer.
True or False: Patients with PIK3CA-mutated TNBC have better outcomes than those with PIK3CA-mutated HR+/HER2-negative metastatic breast cancer.
True or False: Patients with...
08/15/2020
Oncology
Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
Quiz
Tiragolumab Plus Atezolizumab and Chemotherapy in ES-SCLC
06/19/2026
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory biomarker results from the phase 3 SKYSCRAPER-02C trial, which tumor characteristics were associated with a potentially greater benefit from tiragolumab-based therapy in patients with ES-SCLC?
According to exploratory...
06/19/2026
Oncology
Quiz
Safety and Preliminary Activity of Eganelisib in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
06/19/2026
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a phase 1 study evaluating eganelisib in heavily pretreated patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes, what evidence of antileukemic activity was reported...
According to results from a...
06/19/2026
Oncology
Quiz
Polycythemia Vera Management Pre-Survey
06/17/2026
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in this brief survey. Your response will provide valuable insight into how clinicians manage polycythemia vera in clinical practice. 
Thank you for taking part in...
06/17/2026
Oncology
Quiz
Pivekimab Sunirine for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasms
06/09/2026
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA trial supported the FDA approval of pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms?
Which finding from the CADENZA...
06/09/2026
Oncology
Quiz
Durvalumab Plus BCG for BCG-Naïve Patients With Non-Muscle Invasive Bladder Cancer
06/08/2026
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase 3 POTOMAC trial led to the FDA approval of durvalumab plus BCG for BCG-naïve patients with high-risk non–muscle-invasive bladder cancer?
Which key finding from the phase...
06/08/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 4
05/21/2026
Lucia Masarova, MD
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the relationship between leukocytosis, symptom burden, and disease activity in polycythemia vera.
Test your understanding of the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 3
05/21/2026
Lucia Masarova, MD
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent leukocytosis may inform assessment of disease control and management decisions in polycythemia vera.
Learn how persistent...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 2
05/21/2026
Lucia Masarova, MD
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the association between elevated white blood cell count and thrombotic risk in polycythemia vera.
Review evidence evaluating the...
05/21/2026
Oncology
White Blood Cell Count Control in Polycythemia Vera (PV) Management: A Quiz Journey
PV Management Question 1
05/21/2026
Lucia Masarova, MD
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the clinical relevance of white blood cell count control in polycythemia vera management.
Test your knowledge of the...
05/21/2026
Oncology

Recent News

News
Promising Intracranial Activity With Trastuzumab Deruxtecan Among Patients With HER2-Positive/Low Metastatic Breast Cancer With Active Brain Metastases
08/07/2025
Allison Casey
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data, trastuzumab deruxtecan showed promising intracranial activity for patients with active brain metastases from HER2-positive or HER2-low metastatic breast cancer.
According to real-world data,...
08/07/2025
Oncology
News
Real-World Treatment Patterns, Outcomes of Patients With HER2-Low Metastatic Breast Cancer
06/24/2025
Allison Casey
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that patients with HR-positive, HER2-low metastatic breast cancer switched to chemotherapy after receiving 2 lines of therapy.
A retrospective study found that...
06/24/2025
Oncology
News
No Benefit from Addition of Atezolizumab to Standard of Care Among Patients With HER2-Positive Breast Cancer
12/08/2023
Allison Casey
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a phase 3 trial, the addition of atezolizumab to chemotherapy plus trastuzumab and peruzumab did not increase the pathologic complete response among patients with HER2-positive breast cancer.
According to results from a...
12/08/2023
Oncology
News
Trastuzumab Emtansine Improved Survival Among Patients With Residual Invasive HER2-Positive Early Breast Cancer
12/08/2023
Allison Casey
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the KATHERINE trial, trastuzumab emtansine improved the invasive disease-free survival and overall survival among patients with residual invasive HER2-positive early breast cancer when compared with trastuzumab.
According to results from the...
12/08/2023
Oncology
News
Switching From Reference Trastuzumab to Biosimilar for HER2 Positive Breast Cancer May Not Affect Infusion Reaction, Cardiac Dysfunction
07/10/2023
Gina Tomaine
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference trastuzumab to biosimilar trastuzumab may not have a significant effect on the frequency of infusion reaction expression or the occurrence of cardiac dysfunction among patients with HER2-positive breast cancer.
Switching from reference...
07/10/2023
Oncology
News
Cardiac Safety of SB3 Trastuzumab Biosimilar for Patients With HER2-Positive Breast Cancer
05/09/2023
Allison Casey
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3 trastuzumab biosimilar demonstrated comparable cardiac safety to reference trastuzumab among patients with HER2-positive early or locally advanced breast cancer.
In a phase 3 trial, the SB3...
05/09/2023
Oncology
News
Chemotherapy-Free, De-escalated Neoadjuvent Therapy for HR-Positive/HER2-Positive Early Breast Cancer
04/06/2023
Amber Denham
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2 trial found achieving pathologic complete response (pCR) after 12 weeks of chemotherapy-free, de-escalated neoadjuvant therapy was associated with excellent survival in HR-positive/HER2-positive early breast...
Long-term data from a phase 2...
04/06/2023
Oncology
News
No Prognostic, Predictive Value of Young Age for Patients With HER2-Positive Early Breast Cancer
08/12/2022
Derek Cowsert
A study found young age to have no prognostic or predictive value for patients with HER2-positive early breast cancer.
A study found young age to have no prognostic or predictive value for patients with HER2-positive early breast cancer.
A study found young age to have...
08/12/2022
Oncology
News
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Patients With HER2–Positive Breast Cancer
05/05/2022
Allison Casey
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to fam-trastuzumab deruxtecan-nxki for the treatment of adult patients with HER2–positive metastatic or unresectable breast cancer previously treated with an anti-HER2-based regimen.
The FDA granted approval to...
05/05/2022
Oncology
News
Trastuzumab Deruxtecan Outperforms Standard of Care in Previously Treated HER2–Positive, Metastatic Breast Cancer
04/14/2022
John Otrompke, BA, JD
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab deruxtecan was associated with significantly lower risk of disease progression or death over trastuzumab emtansine in patients with HER2–positive, metastatic breast cancer.
Treatment with trastuzumab...
04/14/2022
Oncology
News
Early-Phase Data Support Further Evaluation of Daraxonrasib in RAS-Mutant Non-Small Cell Lung Cancer
09/03/2026
Stephanie Holland
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that daraxonrasib produced meaningful antitumor activity across dose levels in previously treated advanced RAS-mutant non–small cell lung cancer, supporting further evaluation of this oral RAS(ON) multiselective...
Early-phase results showed that...
09/03/2026
Oncology
News
Etentamig Significantly Reduces Risk of Progression or Death in Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
09/03/2026
Stephanie Holland
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3 CERVINO trial showed that etentamig significantly improved response and progression-free survival over standard available therapies in triple-class exposed relapsed or refractory multiple myeloma, supporting...
Topline results from the phase 3...
09/03/2026
Oncology
News
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in EGFR-Mutated Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi trial showed that ivonescimab plus chemotherapy improved progression-free survival compared with chemotherapy alone in patients with advanced EGFR-mutated NSCLC after progression on third-generation EGFR...
Results from the phase 3 HARMONi...
09/02/2026
Oncology
News
Longer Follow-Up Reinforces Clinical Benefit of Perioperative Durvalumab in Resectable Non-Small Cell Lung Cancer
09/02/2026
Stephanie Holland
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3 AEGEAN trial showed that perioperative durvalumab plus neoadjuvant chemotherapy maintained an event-free survival benefit compared with neoadjuvant chemotherapy alone in patients with resectable non-small cell...
Updated results from the phase 3...
09/02/2026
Oncology
News
Perioperative Pembrolizumab Nearly Doubles 5-Year Event-Free Survival in Patients With Resectable Non-Small Cell Lung Cancer
09/01/2026
Stephanie Holland
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase 3 KEYNOTE-671 trial showed that perioperative pembrolizumab plus neoadjuvant chemotherapy provided durable event-free and overall survival benefits compared with neoadjuvant chemotherapy and surgery alone in...
Five-year results from the phase...
09/01/2026
Oncology
News
NEO100-01 Meets Primary End Point, Supporting Further Development in IDH1-Mutant Glioma
08/31/2026
Emily Estrada
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase 2a NEO100-01 trial showed that intranasal NEO100 achieved a 48.9% 6-month progression-free survival rate in patients with recurrent IDH1-mutant high-grade glioma, significantly exceeding the prespecified 20%...
Topline results from the phase...
08/31/2026
Oncology
News
Zanidatamab Plus Chemotherapy Improves Overall Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
08/31/2026
Stephanie Holland
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01 results showed that zanidatamab-based regimens improved overall survival compared with trastuzumab plus chemotherapy in first-line HER2-positive advanced gastroesophageal adenocarcinoma, strengthening the...
Updated phase 3 HERIZON-GEA-01...
08/31/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology
FDA Approval
FDA Approves First-in-Class Rusfertide to Reduce Phlebotomy Burden in Adult Patients With Polycythemia Vera
08/31/2026
Emily Estrada
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide for the treatment of erythrocytosis in adult patients with polycythemia vera after results from the phase 3 VERIFY trial showed showed improved hematocrit control, reduced phlebotomy requirements, and improved...
The FDA has approved rusfertide...
08/31/2026
Oncology
FDA Approval
FDA Approves Ropeginterferon Alfa-2b for Adult Patients With Essential Thrombocythemia
08/31/2026
Emily Estrada
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the SURPASS ET trial, the FDA has approved ropeginterferon alfa-2b for adult patients with essential thrombocythemia regardless of genotype or disease status, marking the first new FDA-approved treatment for the disease...
Based on results from the...
08/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use